An experimental nasal spray has helped clear toxic protein buildups in the brains of mouse models of Alzheimer's. Its ...

For now, after obtaining approval for early stages of cognitive decline and dementia, lecanemab and donanemab continue their ...

Our Director of Research Dr Sheona Scales describes her four highlights from this year's Clinical Trials on Alzheimer's ...

Alzheimer’s trials face the unique challenge of studying participants with cognitive decline, amid a move towards digital ...

The $74.5 million grant will fund a study focused on an inherited genetic mutation that has been linked to Alzheimer's.

AI-driven MRI solution, icobrain aria receives US FDA clearance for safer Alzheimer’s treatment: Boston Saturday, November 16, 2024, 16:00 Hrs [IST] icometrix, a g ...

A single course of newly approved Alzheimer's drug donanemab-azbt, the second medicine available in Japan targeting proteins in the brains of sufferers of the debilitating disease, will cost 3.08 ...

Anti-amyloid antibodies lecanemab and donanemab are in clinical use now, but that does not mean research on them has stopped. At the Clinical Trials on Alzheimer’s Disease conference, held October ...

Following a re-evaluation, the EMA has recommended Eisai and Biogen’s Alzheimer’s therapy Leqembi for a subgroup of patients.

Donanemab became the second Alzheimer's drug that targets causative deposited plaque in the brain to win the coverage after ...

The association said new treatments have become available that slow the progression of Alzheimer’s for those in the early ...

We recently published a list of 10 Best Stocks to Buy According to Billionaire Ken Fisher. In this article, we are going to ...